Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Reports 2008 Results
Sales in local currencies increased by 12% in 2008 and by 9% in Danish kroner. Sales of modern insulins increased by 28% (24% in Danish kroner). Sales of
Sales in local currencies increased by 12% in 2008 and by 9% in Danish kroner. Sales of modern insulins increased by 28% (24% in Danish kroner). Sales of
The Global Initiatives for Proliferation Prevention (GIPP) program under Department of Energy’s National Nuclear Security Administration (NNSA) and AMIC will each contribute $760,000 to the project. The new
The commercial operations and product distribution rights to be acquired by GSK represent approximately 3-4% of UCB’s 2008 expected revenue of at least E3.3 billion. Further details of
The proposed Phase I study is a multi-center, open label, dose escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP in patients with advanced
The company has reported net sales of $3.13 billion for the fourth quarter of 2008, an increase of 4%, compared to $3 billion posted in the fourth quarter
Genpharm has also received final FDA approval for its abbreviated new drug application (ANDA) for a separate lamotrigine product, lamotrigine tablets chewable dispersible (CD). Mylan Pharmaceuticals’s and Genpharm’s
The company reported GAAP earnings per share from continuing operations of $0.29. On a non-GAAP basis, which includes the adjustments noted in the attached reconciliation, the company announced
PT1.2 is based on a new class of antibacterial proteins called small, acid-soluble spore proteins (SASP) which bind to bacterial DNA resulting in rapid ‘speed of kill’. Phico
The funds serve as a milestone payment to Omeros for having successfully met preclinical compound optimization criteria. Omeros’s schizophrenia product candidates inhibit the phosphodiesterase 10 (PDE10) enzyme. Omeros
According to the company, Pearl fractional is the only fractional ablative laser based on the 2,790nm wavelength with proprietary YSGG technology. Pearl fractional received FDA clearance and CE